Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHRS GH Research	$12.54 +7.4%	$11.17	$6.00 ▼ $20.50	$607.69M	0.97	190,858 shs	198,365 shs
MRVI Maravai LifeSciences	$2.23 +5.7%	$2.11	$1.67 ▼ $10.03	$537.33M	0.25	2.33 million shs	2.46 million shs
SLS SELLAS Life Sciences Group	$1.77 +3.5%	$1.59	$0.77 ▼ $2.12	$170.62M	2.25	1.59 million shs	2.41 million shs
VERV Verve Therapeutics	$11.17 +0.5%	$5.76	$2.86 ▼ $11.41	$990.38M	1.67	2.39 million shs	2.99 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHRS GH Research	-5.12%	-8.18%	+4.57%	-6.78%	-1.02%
MRVI Maravai LifeSciences	+2.43%	-2.31%	-4.95%	-8.26%	-70.86%
SLS SELLAS Life Sciences Group	+11.04%	+6.21%	-9.52%	+40.16%	+40.16%
VERV Verve Therapeutics	+0.45%	+77.19%	+154.82%	+90.24%	+110.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHRS GH Research	1.2869 of 5 stars	3.5	0.0	0.0	2.5	0.8	0.0
MRVI Maravai LifeSciences	3.918 of 5 stars	3.1	3.0	4.4	1.2	0.8	1.3
SLS SELLAS Life Sciences Group	0.2872 of 5 stars	0.0	1.0	0.0	1.4	1.7	0.6
VERV Verve Therapeutics	2.9843 of 5 stars	4.2	1.0	0.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHRS GH Research	3.00	Buy	$32.00	155.18% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	197.71% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A
VERV Verve Therapeutics	2.38	Hold	$14.75	32.05% Upside

Current Analyst Ratings Breakdown

Latest SLS, MRVI, VERV, and GHRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MRVI Maravai LifeSciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/13/2025	MRVI Maravai LifeSciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
MRVI Maravai LifeSciences	$259.18M	2.19	$0.65 per share	3.41	$2.28 per share	0.98
SLS SELLAS Life Sciences Group	$1M	176.61	N/A	N/A	$0.13 per share	13.62
VERV Verve Therapeutics	$32.33M	30.80	N/A	N/A	$5.83 per share	1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHRS GH Research	-$38.96M	-$0.79	N/A	N/A	N/A	N/A	-19.20%	-18.40%	9/2/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/6/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest SLS, MRVI, VERV, and GHRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHRS GH Research	N/A	29.71	29.71
MRVI Maravai LifeSciences	0.60	5.96	5.17
SLS SELLAS Life Sciences Group	N/A	4.64	4.64
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHRS GH Research	56.90%
MRVI Maravai LifeSciences	50.25%
SLS SELLAS Life Sciences Group	17.38%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
GHRS GH Research	N/A
MRVI Maravai LifeSciences	2.11%
SLS SELLAS Life Sciences Group	1.20%
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHRS GH Research	10	52.03 million	N/A	Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.58 million	Not Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable

SLS, MRVI, VERV, and GHRS Headlines

Recent News About These Companies

VERV Verve Therapeutics, Inc. - Seeking Alpha

June 24 at 10:42 PM | seekingalpha.com

Eli Lilly's Strategic Acquisition of Verve Therapeutics

June 24 at 5:41 PM | pharmiweb.com

GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

June 24 at 3:08 AM | marketbeat.com

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

June 23 at 2:58 AM | insidermonkey.com

Research Analysts Offer Predictions for VERV Q2 Earnings

June 21 at 1:17 AM | americanbankingnews.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20, 2025 | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20, 2025 | globenewswire.com

Lifesci Capital Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Rating Lowered to "Neutral" at HC Wainwright

June 20, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Downgraded to "Hold" Rating by Jefferies Financial Group

June 20, 2025 | americanbankingnews.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19, 2025 | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19, 2025 | insidenova.com

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19, 2025 | msn.com

Verve Therapeutics (NASDAQ:VERV) Lowered to Hold Rating by William Blair

June 19, 2025 | americanbankingnews.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18, 2025 | businesswire.com

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

June 18, 2025 | zacks.com

Verve Therapeutics (NASDAQ:VERV) Receives Neutral Rating from HC Wainwright

June 18, 2025 | marketbeat.com

Lifesci Capital Reaffirms "Market Perform" Rating for Verve Therapeutics (NASDAQ:VERV)

June 18, 2025 | marketbeat.com

Verve Therapeutics' (VERV) "Hold" Rating Reiterated at Jefferies Financial Group

June 18, 2025 | marketbeat.com

Lock In The 81.5% Run - Initiating Verve With A Sell

June 18, 2025 | seekingalpha.com

Verve Therapeutics (NASDAQ:VERV) Sets New 12-Month High - Here's Why

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, MRVI, VERV, and GHRS Company Descriptions

GH Research NASDAQ:GHRS

$12.54 +0.86 (+7.36%)

Closing price 04:00 PM Eastern

Extended Trading

$12.64 +0.10 (+0.80%)

As of 07:35 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Maravai LifeSciences NASDAQ:MRVI

$2.23 +0.12 (+5.69%)

Closing price 04:00 PM Eastern

Extended Trading

$2.22 0.00 (-0.22%)

As of 06:47 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.77 +0.06 (+3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.75 -0.02 (-1.13%)

As of 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Verve Therapeutics NASDAQ:VERV

$11.17 +0.06 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$11.14 -0.03 (-0.23%)

As of 08:00 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time